Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
Harold J. Burstein(Dana-Farber Cancer Institute), Binghe Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Judy E. Garber(Dana-Farber Cancer Institute), Boon Chua, David Cameron(Corewell Health), Meredith M. Regan(Dana-Farber Cancer Institute), Florian Fitzal, Eva Ciruelos, Sara Y. Brucker(University Children's Hospital Tübingen), Philip Poortmans(University of Antwerp), Fátima Cardoso(Breast Cancer Alliance), Michael Gnant(Austrian Breast & Colorectal Cancer Study Group), Viviana Galimberti, Prudence A. Francis(Peter MacCallum Cancer Centre), Nadia Harbeck(Breast Center), Chiun‐Sheng Huang(National Taiwan University Hospital), Carsten Denkert(Philipps University of Marburg), Bent Ejlertsen, Ann H. Partridge(Dana-Farber Cancer Institute), Lisa A. Carey(University of North Carolina at Chapel Hill), Marco Colleoni(European Institute of Oncology), Hervé Bonnefoi, Bahadır M. Güllüoğlu(Marmara University), Beat Thürlimann(University of St.Gallen), Jens Huober(University of St.Gallen), Eric P. Winer(University of Vermont), Jonas Bergh(Karolinska Institutet), Zefei Jiang, Peter Dubsky(Hirslanden Klinik St. Anna), Monica Morrow(Memorial Sloan Kettering Cancer Center), Denisse Bretel Morales, William P. Weber(University of Basel), Suzette Delaloge(Institut Gustave Roussy), William J. Gradishar(Northwestern University), André Ilbawi(World Health Organization), Martine Piccart(Université Libre de Bruxelles), Sibylle Loibl(Goethe University Frankfurt), Aleix Prat(Hospital Clínic de Barcelona), Hebatallah Gamal El Din Mohamed Mahmoud, Carlos Barrios(Hospital São Lucas da PUCRS), Steven Johnston, Fabrice André(Inserm), H.-J. Senn(Breast Center), Giuseppe Curigliano(European Institute of Oncology)
Cited by 799
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k